Literature DB >> 22371609

Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy.

Hyun Su Kim1, Kyung Soo Lee, Won-Jung Koh, Kyeongman Jeon, Eun Ju Lee, Hee Kang, Joonghyun Ahn.   

Abstract

PURPOSE: To present the serial computed tomographic (CT) findings of lung abnormalities in Mycobacterium massiliense pulmonary disease compared with those in Mycobacterium abscessus disease.
MATERIALS AND METHODS: The institutional review board approved this retrospective study and waived informed consent. Serial chest CT scans of M massiliense (n = 34) and M abscessus (n = 24) pulmonary diseases were retrospectively reviewed. Patients were treated with clarithromycin-containing combination antibiotics regimen, and sputum examinations were performed regularly. CT scans were obtained at the beginning of antibiotic therapy, at the end of 4-week hospitalization, and at the time of 12-month antibiotic therapy.
RESULTS: All patients with M massiliense disease had sputum conversion during treatment, whereas 50% of patients with M abscessus disease had sputum conversion. The most common CT findings of M massiliense disease at presentation were cellular bronchiolitis (n = 34, 100%), bronchiectasis (n = 34, 100%), consolidation (n = 33, 97%), nodules (n = 32, 94%), and cavities (n = 15, 44%). These findings were similar in M abscessus disease. Thirty (88%) patients with M massiliense disease had decrease in overall CT score at 12-month therapy, whereas only eight (33%) patients with M abscessus disease had a decrease (P < .0001). Improvement was noticeable in cellular bronchiolitis and cavity in M massiliense disease.
CONCLUSION: Common CT findings of M massiliense diseases overlap with those of M abscessus disease. However, responses to antibiotic treatment are much different; in M massiliense disease, negative sputum conversion is accomplished in all patients and serial CT scans show improvement in most patients. © RSNA, 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371609     DOI: 10.1148/radiol.12111374

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  26 in total

1.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only.

Authors:  W-J Koh; K Jeon; S J Shin
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

3.  Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.

Authors:  Bumhee Yang; Byung Woo Jhun; Seong Mi Moon; Hyun Lee; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Su-Young Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Shannon Novosad; Emily Henkle; Kevin L Winthrop
Journal:  Curr Pulmonol Rep       Date:  2015-07-12

6.  Treatment of Non-Tuberculous Mycobacterial Lung Disease.

Authors:  Julie V Philley; Mary Ann DeGroote; Jennifer R Honda; Michael M Chan; Shannon Kasperbauer; Nicholas D Walter; Edward D Chan
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-11

Review 7.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

8.  Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense.

Authors:  Go-Eun Choi; Ki-Nam Min; Choul-Jae Won; Kyeongman Jeon; Sung Jae Shin; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

9.  Nontuberculosis mycobacterium disease is a risk factor for chronic obstructive pulmonary disease: a nationwide cohort study.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Fung-Chang Sung; Christine Yi-Ting Chou; Chia-Hung Kao
Journal:  Lung       Date:  2014-04-02       Impact factor: 2.584

10.  Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease.

Authors:  Hyung Koo Kang; Hye Yun Park; Dohun Kim; Byeong-Ho Jeong; Kyeongman Jeon; Jong Ho Cho; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Won-Jung Koh
Journal:  BMC Infect Dis       Date:  2015-02-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.